BioFrontier Partners, Inc.
Venture capitalTokyo · Series A–Late Stage · 11 people tracked
Investment thesis
BioFrontier Partners, Inc. is a Japanese venture capital firm that supports and invests in bio and life science-related businesses.
Source: firm website, verified Jul 29, 2026.
Team · 11 people
from the firm's website & public directories
Frequently asked questions
- What stage does BioFrontier Partners, Inc. invest at?
- BioFrontier Partners, Inc. invests at the Series A, Series B, Series C, Late Stage stages.
- What is BioFrontier Partners, Inc.'s typical check size?
- BioFrontier Partners, Inc. typically writes checks of $500K – $3M.
- What sectors does BioFrontier Partners, Inc. focus on?
- BioFrontier Partners, Inc. focuses on Biotech, Medical Devices.
- Where is BioFrontier Partners, Inc. located?
- BioFrontier Partners, Inc. is headquartered in Tokyo, JP.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Pappas Capital is a life sciences venture capital firm that invests in and helps build companies developing next-generation life science products and technologies.
Excel Venture Management is a venture capital firm that builds and invests in companies applying life science technologies to problems in healthcare and other areas.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.